VS 025
Alternative Names: VS-025Latest Information Update: 14 Dec 2021
At a glance
- Originator University of Florida Research Foundation
- Developer Nuvara Therapeutics
- Class Amino acids
- Mechanism of Action Epithelial sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome
Most Recent Events
- 14 Dec 2021 Nuvara Therapeutics plans preclinical studies in first animal model for acute respiratory distress syndrome in USA in 2023 (Nuvara Therapeutics pipeline, December 2021)
- 14 Dec 2021 Nuvara Therapeutics plans preclinical studies in second animal model for acute respiratory distress syndrome in USA in 2024 (Nuvara Therapeutics pipeline, December 2021)
- 01 Jan 2021 Preclinical trials in Adult respiratory distress syndrome in USA (unspecified route) (Nuvara Therapeutics pipeline, December 2021)